Skip to main content
Clinical Trials/JPRN-UMIN000003979
JPRN-UMIN000003979
Recruiting
未知

A pilot study of efficacy and safety of aprepitant with chemoradiotherapy involving weekly cisplatin in patients with cervical cancer. - A pilot study of aprepitant with CCRT

ara Medical University0 sites30 target enrollmentAugust 6, 2010
Conditionscervical cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
cervical cancer
Sponsor
ara Medical University
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 6, 2010
End Date
March 31, 2014
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ara Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. patients with received pimozide. 2\. patients with history of chemotherapy with cisplatin. 3\. patients with vomiting within 24 hours before first administrating of cisplatin. 4\. patients who have had any other cancer. 5\. patients who are pregnant or breast feeding. 6\. patients with severe complications (heart disease, uncontrolled diabetes,bleeding tendency). 7\. patients with active infection disease whom steroid is inappropriate for. 8\. patients who have a history of hypersensitivity to drugs. 9\. patients who were administered drugs in the following, 5\-HT3 blocker, phenothiazine, butyrophenone, benzamide, dopamine receptor antagonist. 10\. patients who are considered to be inappropriate for this study judged by the treating physician.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A phase I/II study for the safety and efficacy of Panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapyunresectable advanced colorectal cancer
JPRN-UMIN000019876Takeda Pharmaceutical Company Limited52
Active, not recruiting
Not Applicable
A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD). - Resistant Depression StudyMajor Depressive DisorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOS
EUCTR2008-003359-58-GBCPS Research60
Completed
Not Applicable
Safety and efficacy of Transcend CyPass glaucoma implant in open angle glaucoma patients who have failed medical treatmentPrimary open angle glaucomaEye DiseasesGlaucoma
ISRCTN23263504Transcend Medical, Inc.™ (USA)20
Completed
Not Applicable
Transcend CyPass glaucoma implant and cataract surgery in open angle glaucoma patients
ISRCTN86839890Transcend Medical, Inc.™ (USA)20
Active, not recruiting
Phase 1
A preliminary study to assess if low dose iron is safe and effective in patients with inflammatory bowel diseaseIron deficiency anaemia in inflammatory bowel diseaseMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851MedDRA version: 20.1Level: PTClassification code 10021972Term: Inflammatory bowel diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2018-002982-20-GBRoyal Liverpool University Hospital30